Grace Therapeutics

GRCE · NASDAQ

$1.98+$0.10 (+5.32%)TodayMarket closed ·
Prev close $1.88

Who owns GRCE

Largest institutional holders, from their latest 13F filings

The 10 largest institutions hold 36.6% of GRCE’s shares.

  • Shore Pharma LLC7.3%
  • Adar1 Capital Management LLC5.9%
  • SS Pharma LLC5.7%
  • Rajitha Grace 2018 Irrevocable Trust4.8%
  • Next 6 largest institutions12.9%
  • All other shareholders63.4%
Top institutional holders of GRCE
HolderShares% of shares
Shore Pharma LLC1.19M7.30%
Adar1 Capital Management LLC959.57K5.90%
SS Pharma LLC931.74K5.73%
Rajitha Grace 2018 Irrevocable Trust781.59K4.80%
BofA Global Research (US)494.70K3.04%
Kottayil (George)494.70K3.04%
AIGH Capital Management, LLC.478.25K2.94%
Kavuru (Vimal)426.32K2.62%
Worth Venture Partners, LLC162.83K1.00%
Neugeboren (Edward)37.90K0.23%

Largest mutual fund holders

Top mutual fund holders of GRCE
HolderShares% of shares
Vanguard Total Stock Market Index Fund225.00K1.38%
Fidelity NASDAQ Composite Index Fund3.06K0.02%

Insider trades

Form 4 filings by officers, directors and large holders

Over the last 6 months, insiders bought $639.56K (18 trades) of GRCE on the open market, with no sales.

Latest GRCE insider transactions
InsiderTypeSharesValue
Opaleye Management Inc.Buy36.35K$68.76K
Opaleye Management Inc.Buy23.48K$45.69K
Opaleye Management Inc.Buy11.23K$21.73K
Opaleye Management Inc.Buy7.21K$14.57K
Opaleye Management Inc.Buy5.34K$10.92K
Opaleye Management Inc.Buy2.08K$4.19K
Opaleye Management Inc.Buy1.69K$3.49K
Opaleye Management Inc.Buy20.00K$41.37K
Opaleye Management Inc.Buy38.80K$78.96K
Opaleye Management Inc.Buy7.85K$16.40K

Short interest

Settled Sep 30, 2026

Shares short
1.72M
Days to cover
19.03
% of shares outstanding
10.58%
Average daily volume
90.44K
Change since last report
−2.5%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.